Search or ask a question

How to treat cirrhosis of the liver naturally?

Portal venous pressure

Intraperitoneal injection

Answers from top 3 papers

PDF

Open Access

More filters

Papers (3)	Insight
Journal Article•DOI Administration of rhHGF-Activator Via Portal Vein Stimulates the Regeneration of Cirrhotic Liver After Partial Hepatectomy in Rats1 Hidesuke Yanagida, Masaki Kaibori, Takeshi Hijikawa, A-Hon Kwon, Yasuo Kamiyama, Tadayoshi Okumura - Show less +5 more 01 Jan 2006-Journal of Surgical Research 9 Citations	It may be potentially useful treatment for patients with liver cirrhosis.
Journal Article•DOI Development of a new animal model of liver cirrhosis in swine. Jun-Jing Zhang, X.-K. Meng, Chaoxuan Dong, J.-L. Qiao, R.-F. Zhang, G.-Q. Yue, H.-Y. Zhong - Show less +6 more 01 Jan 2009-European Surgical Research 24 Citations	In conclusion, this study was successful in producing liver cirrhosis and offers an ideal experimental model for observing surgical therapeutic efficacy.
Journal Article•DOI Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis. Koichi Kozaki, Masahiro IInuma, Tomoyuki Takagi, Takanori Fukuda, Takaya Sanpei, Yusuke Terunuma, Yoshiharu Yatabe, Kazuhiro Akano - Show less +7 more 01 Aug 2016-Therapeutic Apheresis and Dialysis 30 Citations	CART can be effectively applied as a palliative procedure for refractory ascites of decompensated liver cirrhosis patients.

My columns

Related Questions

What are the necessary prophylactic treatments in patients with cirrhosis?2 answersPhương pháp điều trị dự phòng ở bệnh nhân xơ gan bao gồm dự phòng kháng sinh để giảm nguy cơ kết quả bất lợi trong chảy máu đường tiêu hóa trên (UGIB). Quinolone, beta-lactam đơn độc hoặc kết hợp có thể được sử dụng ở bệnh nhân xơ gan bị UGIB. Ngoài ra, liệu pháp chống đông máu có thể được xem xét để ngăn ngừa các biến chứng huyết khối như huyết khối tĩnh mạch cửa và huyết khối tắc mạch tĩnh mạch ở bệnh nhân xơ gan có nguy cơ huyết khối cao. Thuốc chẹn beta không chọn lọc (NSBBs) hoặc thắt dây nội soi (EBL) có thể được sử dụng để ngăn ngừa chảy máu tĩnh mạch, với NSBBs là phương pháp điều trị đầu tiên. Trong trường hợp NSBB bị chống chỉ định hoặc không dung nạp, EBL có thể được sử dụng. Có thể cần thiết phải điều trị nội tạng nội gan (TIPS) đối với những bệnh nhân chảy máu không kiểm soát được hoặc khó kiểm soát. Dự phòng thứ phát cho chảy máu tĩnh mạch liên quan đến sự kết hợp của NSBBs và EBL, với TIPS là một lựa chọn cho những bệnh nhân thất bại trong điều trị kết hợp.

How do you treat cirrhosis of the liver naturally?3 answers

How to heal cirrhosis of liver naturally?4 answers

What foods heal cirrhosis of the liver?3 answers

What is the best home remedy for cirrhosis?8 answers

What is the best treatment for liver cirrhosis in Ayurveda?3 answers

See what other people are reading

How chronic kidney disease (CKD) can influence the toxicological effects of drugs primarily excreted by the kidneys?

Chronic kidney disease (CKD) can significantly impact the toxicological effects of drugs primarily excreted by the kidneys. Patients with CKD may experience altered pharmacokinetic profiles due to changes in drug metabolism and transport processes in the kidneys and liver. Uremic toxins and inflammatory cytokines associated with CKD can affect the activity and expression levels of drug-metabolizing enzymes and transporters, potentially leading to fluctuations in drug concentrations and toxicity. Some drugs, like proton pump inhibitors, antibiotics, and diuretics, are known to cause nephrotoxicity and may exacerbate CKD progression. Therefore, close monitoring and dosage adjustments are crucial to mitigate the risk of drug-induced harm in CKD patients.What data paper show the activity of pri.ed neutrophils in sepsis?

The activity of neutrophils in sepsis has been extensively studied in various research papers. A systematic review highlighted reduced migration capacity and delayed apoptosis of neutrophils in sepsis, with conflicting evidence on phagocytic activity. Bioinformatics analysis identified key biomarkers like AKT1, MMP9, and ARG1, along with regulatory networks involving miRNAs and transcription factors, as potential diagnostic markers for sepsis. Transcriptomic analysis using a reporter assay demonstrated distinct gene expression profiles in neutrophils from septic patients, correlating with disease severity and outcomes, suggesting a potential for predicting and managing sepsis. Proteomic analysis in decompensated cirrhosis patients with sepsis revealed altered expression of proteins associated with neutrophil activation and autophagy, indicating potential therapeutic targets for improving neutrophil functionality in sepsis. Single-cell gene sequencing in a mouse sepsis model identified immunosuppressive subsets of neutrophils with inhibitory functions, shedding light on the heterogeneity and immunomodulatory roles of neutrophils in sepsis.What is the effectiveness of zingiber officinale tea on diegstion?

Zingiber officinale, commonly known as ginger, has shown promising effects on various health aspects. Studies indicate that Z. officinale can positively impact cardiovascular health by improving dyslipidaemia and reducing inflammation. Additionally, Z. officinale has been found to reduce serum inflammatory markers like procalcitonin and neutrophil-lymphocyte ratio in patients with pneumonia. Furthermore, research suggests that Z. officinale has favorable antioxidant properties in the brain, reducing oxidative stress markers and enhancing antioxidant levels. Moreover, in diabetic patients, Z. officinale has been shown to significantly reduce fasting blood sugar and HbA1c levels, indicating its potential in managing diabetes. While the data supports various health benefits of Z. officinale, its direct effectiveness on digestion specifically was not addressed in the provided contexts.Which specific microRNAs have been found to be dysregulated in individuals with obesity and metabolic inflexibility?

Several microRNAs (miRNAs) have been identified as dysregulated in individuals with obesity and metabolic inflexibility. In obese individuals with metabolic syndrome, miR-331-3p, miR-452-3p, and miR-485-5p were found to be over-expressed, while miR-153-3p, miR-182-5p, and miR-433-3p were under-expressed. Additionally, miRNAs 122 and 192 were significantly correlated with markers of inflammation and metabolic disorders in pediatric obesity. Furthermore, in response to a high-carbohydrate meal, miR-15a-5p and miR-17-5p levels were altered in healthy weight individuals but remained unchanged in overweight insulin-resistant women, indicating a potential link to metabolic inflexibility. These dysregulated miRNAs play crucial roles in metabolic regulation and may serve as markers for identifying individuals predisposed to metabolic diseases associated with obesity.What is questionnire?

A questionnaire is a structured set of questions designed to gather specific information from individuals. It serves as a tool for data collection and research purposes. In the context of the provided abstracts, questionnaires play a crucial role in various fields such as real-time assessment of student learning, biomedical research to formulate research questions, prognostication in healthcare settings, and assessing general health using instruments like the General Health Questionnaire (GHQ-28). Questionnaires help in obtaining valuable insights, identifying trends, and making informed decisions based on the responses collected. They are essential for understanding patient outcomes, evaluating health status, and exploring factors influencing various phenomena across different disciplines.Does PAR1 plays role in ROS in kidney?

Protease-activated receptor 1 (PAR1) plays a significant role in the regulation of reactive oxygen species (ROS) in the kidney, impacting various aspects of kidney health and disease. The activation of PAR1 has been implicated in the pathogenesis of diabetic nephropathy (DN), where it contributes to kidney damage through mechanisms involving increased mesangial proliferation and extracellular matrix production, suggesting that PAR1 activation exacerbates the oxidative stress-related pathologies in DN. Conversely, the inhibition of PAR1 has been shown to ameliorate diabetic nephropathy in a PAR-1-dependent manner, indicating that PAR1's role in kidney disease is complex and may depend on the context of its activation or inhibition. Furthermore, the involvement of PAR1 in acute kidney injury and chronic kidney disease is highlighted by its interaction with oxidative stress pathways. Oxidative stress, a condition characterized by excessive ROS, plays a vital role in the progression of both acute and chronic kidney diseases. The activation or inhibition of PAR1 leads to glomerular hematuria and subsequent acute tubular epithelial cell injury, underscoring the importance of PAR1's normal function in maintaining the glomerular filtration barrier integrity and suggesting its potential involvement in oxidative stress mechanisms within the kidney. Additionally, the broader context of ROS in kidney health, including the roles of various enzymes and receptors in modulating oxidative stress, such as the involvement of poly(ADP-ribose) polymerase 1 (PARP1) and sirtuin 3 (SIRT3) in cisplatin nephrotoxicity, further illustrates the complex interplay between oxidative stress and kidney function. The decrease in antioxidant defense mechanisms, as seen with lower paraoxonase 1 (PON1) activity in patients with chronic kidney disease, also highlights the critical balance of oxidative and antioxidative forces in kidney pathology. In summary, PAR1 plays a multifaceted role in the regulation of ROS in the kidney, influencing the progression of kidney diseases through mechanisms that involve both the exacerbation and amelioration of oxidative stress, depending on the specific pathological context and the balance of signaling pathways activated or inhibited.Does PAR1 plays role in NO in kidney?

Protease-activated receptor 1 (PAR1) plays a multifaceted role in kidney function and pathology, with implications for nitric oxide (NO) involvement in renal hemodynamics and disease processes. PAR1's activation has been linked to various renal outcomes, including the regulation of renal hemodynamics, fibrosis, and inflammation, which are critical in the progression of chronic kidney diseases (CKDs) and diabetic nephropathy (DN). In the context of renal hemodynamics, PAR1 activation by thrombin has been shown to decrease plasma renin activity, suggesting a role in the modulation of renal blood flow and filtration processes. This effect is mediated through a reduction in perfusate flow and inhibition of renin secretion rates, which are crucial for maintaining blood pressure and fluid balance. The involvement of NO in these processes is suggested by the action of PAR2, a related receptor, which, upon activation, increases renin secretion and perfusate flow in a manner that is markedly attenuated by NO synthase inhibition. Although this evidence directly pertains to PAR2, it implies a broader interaction between PARs and NO in the kidney, suggesting that PAR1 may also influence NO-mediated pathways indirectly. Furthermore, PAR1's role in renal disease progression, particularly in DN and CKD, highlights its impact on inflammatory and fibrotic pathways. The activation of PAR1 in renal fibrosis models leads to the induction of epithelial-mesenchymal transition (EMT) and extracellular matrix (ECM) deposition, processes that are critical for fibrosis development. While the direct link between PAR1 activation and NO in these contexts is less clear, the overall involvement of PAR1 in renal inflammation and fibrosis suggests a complex interplay with NO, given NO's known anti-inflammatory and anti-fibrotic effects. In summary, while direct evidence of PAR1's role in modulating NO in the kidney is limited, its involvement in regulating renal hemodynamics, inflammation, and fibrosis indirectly suggests a potential interaction with NO-mediated pathways. Further research is needed to elucidate the specific mechanisms by which PAR1 influences NO in the kidney.What are the current research findings on the use of lithium augmentation in the treatment of depression?

Current research findings suggest that lithium augmentation is a valuable option in the treatment of depression, particularly in older adults with treatment-resistant depression. Studies have shown that lithium augmentation can significantly improve psychological well-being and increase the remission rates in patients with treatment-resistant depression. Additionally, patient experiences of lithium augmentation have been predominantly positive, with clinical monitoring being perceived favorably. Furthermore, in rodent models, lithium augmentation has been found to enhance the antidepressant effects of ketamine, particularly in nonresponsive individuals, by improving behavioral responses under stress and influencing insulin signaling in the prefrontal cortex. Despite concerns about kidney toxicity in geriatric patients, the benefits of lithium augmentation in depression treatment seem to outweigh the risks.How effective is carabao grass in reducing creatinine levels in individuals with chronic kidney disease?

Carabao grass, also known as Paspalum conjugatum, has shown promising effects in reducing creatinine levels in individuals with chronic kidney disease (CKD) through alternative therapies involving plant extracts. Studies have highlighted the importance of plant-based treatments in ameliorating kidney dysfunction by targeting inflammation, fibrosis, and oxidative stress, which are key processes in CKD pathogenesis. Research indicates that individuals consuming plant-centered, high-quality diets experienced less deterioration in kidney function over time, especially in those with initial mild CKD stages. These findings suggest that incorporating carabao grass or similar plant-based interventions into the treatment regimen of CKD patients may offer a beneficial approach to managing creatinine levels and overall kidney health.How does combined heart and kidney transplantation impact kidney allocation?

Combined heart and kidney transplantation (HKT) impacts kidney allocation by presenting challenges in identifying patients with irreversible kidney disease who may not benefit from heart transplantation alone. Patients with advanced heart failure (HF) and concomitant chronic kidney disease (CKD) may require combined HKT, especially those on chronic hemodialysis. The utilization of kidney-after-heart strategy can be considered in patients not needing chronic dialysis, allowing for postoperative monitoring to determine the necessity of combined transplantation. Maximizing kidney graft utility while minimizing operative risks is crucial due to organ scarcity, emphasizing the importance of accurately assessing kidney function recovery potential post-heart transplantation. Additionally, the use of organ perfusion strategies like hypothermic kidney perfusion may optimize outcomes by providing more time for patient stabilization after heart transplant surgery.How does combined heart and kidney transplantation decrease kidney availability?

Combined heart and kidney transplantation (HKT) can decrease kidney availability due to the increased complexity and risks associated with the procedure, impacting the utilization of scarce donor organs. Studies have shown that patients undergoing HKT face challenges such as higher rates of early kidney graft loss, reduced overall survival, and increased risk of kidney graft failure. Additionally, the implementation of new heart allocation policies has been linked to worse patient and graft outcomes in HKT recipients, further highlighting the potential drawbacks of this combined procedure. The decision-making process for selecting between heart transplant alone, simultaneous heart and kidney transplantation (sHKTx), or sequential heart and kidney transplantation involves careful consideration of renal function, patient stability, and long-term outcomes to optimize organ allocation and patient care.